CPHI (China Pharma Holdings, Inc.) שווי פעילות לרווח לפני ריבית, מסים ופחת

China Pharma Holdings (CPHI) generates revenue through the production of affordable generic drugs, although government procurement in the PRC strictly limits its pricing power. Personnel stability is maintained via a high-quality benefits package for Chinese specialists. Profit constraints driven by component costs are evident on the GURU.Markets price chart, where the EV/EBITDA ratio stands at 0.00, confirming the challenges of scaling the business.
פילוחי מדדים מקיפים ואנליטיקה עבור China Pharma Holdings Inc. (CPHI)

This metric determines the total enterprise value including net debt relative to operating profit before depreciation and amortization, measuring the risk premium for capital-intensive assets. Analyzing the EV/EBITDA ratio of the company allows for tracking the issuer's revaluation speed and avoiding the purchase of an asset at the peak of market euphoria. For China Pharma Holdings (CPHI), this metric confirms the resilience of cash flows from generic drug sales even amidst stagnating margins.